^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CSF1R overexpression

i
Other names: CSF1R (Colony stimulating factor 1 receptor)
Entrez ID:
Related biomarkers:
over1year
CSF1R OVEREXPRESSION ACCELLERATES OSTEOSARCOMA TUMOR FORMATION AND GENERATES TUMORS WITH DECREASED IMMUNE CELL INFILTRATION (CTOS 2023)
In conclusion, our findings indicate that overexpression of Csf1r leads to the generation of osteosarcoma tumors with reduced immune presence. This is significant because previous studies have shown that reduced immune presence in osteosarcoma and other sarcoma types is associated with poor patient outcomes. By therapeutically increasing CSF1 levels within tumors, we may promote the proliferation and differentiation of immune cells, potentially improving patient outcomes.
Immune cell
|
TP53 (Tumor protein P53) • CSF1R (Colony stimulating factor 1 receptor)
|
CSF1R overexpression
over1year
A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (CTOS 2023)
In Asian patients with symptomatic TGCT not amenable to improvement with surgery, pexidartinib demonstrated clinical benefit in tumor response and improvement in joint function. The overall safety profile of pexidartinib was comparable with previous data. Hepatotoxicity was manageable with frequent liver test monitoring and dose modifications as defined in the protocol, and no new safety signals were observed in this Asian population.
Clinical • P3 data
|
CSF1R (Colony stimulating factor 1 receptor)
|
CSF1R overexpression
|
Turalio (pexidartinib)
over1year
UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B (CTOS 2023)
With the extension of treatment duration, there is an observed augmentation in the number of pts experiencing sustained tumor shrinkage and favorable safety of Pimicotinib with no apparent hepatotoxicity. Current data confers durable therapeutic benefits in TGCT pts, suggesting that prolonged exposure may represent an optimal treatment approach. In addition, a separate cohort with prior anti-CSF-1/CSF-1R therapies is underway to assess the safety and antitumor activity.
Clinical • P1 data
|
CSF1R (Colony stimulating factor 1 receptor)
|
CSF1R overexpression
|
Conmana (icotinib) • pimicotinib (ABSK021)
over1year
Updates on the Treatment of Tenosynovial Giant Cell Tumor. (PubMed, Hematol Oncol Stem Cell Ther)
Pexidartinib is the first CSF-1 receptor inhibitor approved for the treatment of TGCT. Here, we discuss various available treatment strategies and ongoing investigations and trials targeting diffuse TGCT, which include nilotinib, lacnotuzumab, cabiralizumab, vimseltinib, and emactuzumab.
Review • Journal
|
CSF1R overexpression
|
Tasigna (nilotinib) • Turalio (pexidartinib) • lacnotuzumab (MCS110) • cabiralizumab (BMS-986227) • emactuzumab (RG7155) • vimseltinib (DCC-3014)